Now in it’s third year, ExL Pharma’s Proactive GCP Compliance conference continues to act as the only annual forum for both senior-level clinical quality and clinical operations executives to gather, learn and discuss strategies to achieve and maintain global GCP compliance. Reflecting the industry’s paradigm shift, the 2012 event focuses on risk-based approaches to clinical quality, driven by recently released US and European regulatory guidances.
The model for clinical research is changing, join us in April to learn how to build quality risk management approaches into your clinical operations to ensure quality research, GCP compliance and patient safety.
| Featured Presentations Include: | ||
INDUSTRY KEYNOTE ADDRESS Jeffrey Kasher, PhD, Vice President & COO,Global Clinical Development, | ||
FDA AND EMA GUIDANCES Joanne Spallone, Global Head, Franchise QA, Primary Care & Translational Medicine, NOVARTIS | ||
CASE STUDY – INTEGRATED QUALITY MANAGEMENT PLAN David Nickerson, Senior Director, Clinical Quality Management, | ||
EUROPEAN GCP INSPECTIONS Paul Strickland, Director, Inspections & Intelligence, Global R&D Compliance, AMGEN UK, Chair, Audit Working Party, | ||
CLINICAL CAPAS Elizabeth Luczak, Vice President, Medical Regulatory Compliance, PFIZER, INC. | ||
CASE STUDY - RISK-BASED MANAGEMENT PLAN Sharon Reinhard, Associate Director, Compliance Operations and Oversight, | ||
C-Level, Vice President, Director & Manager level executives from the following departments at Pharma/Biotech/Medical Device companies, CROs and other clinical trial service providers
This conference is also relevant to clinical QA/compliance professionals from: